By Wayne Koberstein, Executive Editor, Life Science Leader magazine
Follow Me On Twitter @WayneKoberstein
Targeting inflammation with molecules emerging from the human microbiome.
Symbiotix Biotherapies is an early pioneer of the microbiome space, preparing to enter clinical- stage development of its lead compound, SYMB-104, for treating MS and inflammatory bowel disease (IBD). It has at least six earlier programs underway with SYMB-104 and another candidate, SYMB-202, seeking a variety of indications for inflammatory, autoimmune, and immuno-oncology conditions. Its proprietary Reglemer technology is based on the most well-studied, microbiome-derived molecule to date, now protected by issued composition- of-matter (COM) patents.